20 May 2022 , 02:44 PM
Net profit of Zydus Lifesciences declined 41.47% to Rs 397.40 crore in the quarter ended March 2022 as against Rs 679.00 crore during the previous quarter ended March 2021. Sales rose 4.49% to Rs 3741.80 crore in the quarter ended March 2022 as against Rs 3580.90 crore during the previous quarter ended March 2021. For the full year,net profit rose 110.32% to Rs 4487.30 crore in the year ended March 2022 as against Rs 2133.60 crore during the previous year ended March 2021. Sales rose 4.97% to Rs 14827.60 crore in the year ended March 2022 as against Rs 14125.00 crore during the previous year ended March 2021.
Particulars | Quarter Ended | Year Ended | ||||
? | Mar. 2022 | Mar. 2021 | % Var. | Mar. 2022 | Mar. 2021 | % Var. |
Sales | 3741.80 | 3580.90 | 4 | 14827.60 | 14125.00 | 5 |
OPM % | 18.78 | 23.11 | – | 22.53 | 23.50 | – |
PBDT | 743.30 | 774.00 | -4 | 5684.10 | 3205.90 | 77 |
PBT | 557.90 | 598.70 | -7 | 4971.10 | 2536.30 | 96 |
NP | 397.40 | 679.00 | -41 | 4487.30 | 2133.60 | 110 |
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.